Catalog No.
Product Name
Application
Product Information
Citations
-
DPP-IV Inhibitor
Vildagliptin is a dipeptidyl peptidase-4 (CD26) inhibitor.- Cecilia Villegas-Novoa, .et al. , Anal Chem, 2022, 94(27):9648-9655 PMID: 35758929
-
DPP-4 Inhibitor
Linagliptin is a DPP-4 inhibitor, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).- Fen Zhuge, .et al. , Exp Neurol, 2024, Mar:373:114689 PMID: 38199510
-
DPP-4 inhibitor
Trelagliptin is a highly selective, long-acting DPP-4 inhibitor.- Ki-Young Kim, .et al. , Pharmaceutics, 2024, Jan 13;16(1):106 PMID: 38258116
-
DPP4 inhibitor
Gemigliptin is a highly selective dipeptidyl peptidase 4 (DPP4) inhibitor with a KD of 7.25 nM.- Ki-Young Kim, .et al. , Pharmaceutics, 2024, Jan 13;16(1):106 PMID: 38258116
-
DPP-4 Inhibitor
Saxagliptin (BMS-477118) is a new dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 50 nM.- Ki-Young Kim, .et al. , Pharmaceutics, 2024, Jan 13;16(1):106 PMID: 38258116
- OHE El-Shoubashy, .et al. , JPC, 2020, 33, 59-70
- Sato T, .et al. , Sci Rep, 2019, Dec 2;9(1):18094 PMID: 31792328
- Chintan N. Koyani, .et al. , Front Physiol, 2018, 9: 1622 PMID: 30487758
- Koyani CN, .et al. , Biochem Pharmacol, 2016, Dec 1;145:64-80 PMID: 28859968
-
DDP-4 inhibitor
Sitagliptin is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.- Zhenhuan Zheng, .et al. , Mol Metab, 2026, Mar 14;106:102340 PMID: 41833222
- Hae Jin Kim, .et al. , Korean J Physiol Pharmacol, 2018, Nov; 22(6): 713-719 PMID: 30402032
- Chintan N. Koyani, .et al. , Front Physiol, 2018, 9: 1622 PMID: 30487758
-
DPP4 Inhibitor
Evogliptin is an orally active inhibitor of DPP4 (dipeptidyl peptidase-4), demonstrating notable and sustained hypoglycemic effects in murine models. In addition to its antidiabetic properties, Evogliptin exerts effects by inhibiting the production of inflammatory and fibrotic signals in hepatocytes through the induction of autophagy. This compound is particularly relevant for research applications related to type 2 diabetes, osteoporosis, renal impairment, and chronic liver inflammation. -
DPP4 Inhibitor
(Rac)-Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP4), exhibiting an IC50 of 19 nM in Caco-2 cell extracts. This compound plays a significant role in the modulation of glucose metabolism, making it relevant for diabetes research. Its ability to enhance insulin secretion and decrease glucagon levels underscores its potential applications in studying metabolic disorders and developing therapeutic strategies for type 2 diabetes. -
DPP-4 Inhibitor
PB01 is a selective DPP-4 inhibitor with an IC50 of 15.66 nM. It effectively reduces high glucose-induced reactive oxygen species (ROS) production and mitochondrial superoxide generation while significantly decreasing cellular DPP-4 expression. In vivo studies demonstrate that PB01 can lower blood glucose levels in diabetic mice, indicating its potential therapeutic application. Furthermore, PB01 exhibits minimal cytotoxicity at a concentration of 100 μM, making it a promising candidate for diabetes-related research. -
DPP-IV Inhibitor
DPP-4-IN-3 is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV), exhibiting an IC50 value of 0.75 nM. This compound demonstrates significant antioxidant properties alongside insulinotropic activity, making it a valuable tool for diabetes research and the study of metabolic disorders. Its ability to modulate the DPP-IV pathway underscores its potential in therapeutic applications aimed at enhancing glucose homeostasis. -
DPPH Scavenger
2,4,7-Trihydroxy-9,10-dihydrophenanthrene is a dihydrophenanthrene derivative primarily targeting DPPH radicals. It exhibits significant antioxidant activity, with an IC50 value of 16.2 μM in DPPH radical-scavenging assays. This compound is useful in research applications focused on antioxidant mechanisms and the study of natural products derived from Pholidota chinensis Lindl. -
DPP4 Inhibitor
Evogliptin tartrate is an orally active DPP4 inhibitor that exhibits significant and sustained hypoglycemic effects in murine models. It not only lowers blood glucose levels but also attenuates the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. This compound is suitable for research applications related to type 2 diabetes, osteoporosis, renal impairment, and chronic liver inflammation. -
DPP IV/CA Inhibitor
DPP IV/hCA II-IN-1 is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) enzymes. This compound exhibits a strong inhibitory effect on DPP IV with an IC50 value of 0.049 μM, while displaying varying Ki values for different carbonic anhydrase isoforms, including 0.0361 μM for CA II. Its dual-target inhibitory activity makes it a valuable tool for studying metabolic disorders and exploring therapeutic avenues in conditions involving DPP IV and CA dysregulation. -
DPP-4 Inhibitor
Gemigliptin tartrate is a selective and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), demonstrating an IC50 of 10.3 nM for human recombinant DPP-4. This compound exhibits significant anti-glycation properties, making it valuable for research into advanced glycation end products (AGEs) and their associated diabetic complications. Its specificity and efficacy position Gemigliptin tartrate as a useful tool in studies aimed at understanding and mitigating the effects of diabetes-related conditions. -
DPP-4 Inhibitor
Saxagliptin hydrochloride is a potent, selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), exhibiting an inhibition constant (Ki) of 0.6-1.3 nM. This compound is primarily employed in research focused on type 2 diabetes mellitus, as it enhances insulin secretion by increasing incretin levels, aiding in glucose regulation. Saxagliptin hydrochloride serves as a valuable tool for studying DPP-4's role in glucose homeostasis and potential therapeutic interventions in diabetes management. -
DPP-4 Inhibitor
Retagliptin is a selective, competitive inhibitor of dipeptidyl peptidase-4 (DPP-4) known for its oral bioavailability. It plays a crucial role in increasing incretin levels, which enhances insulin secretion and lowers glucagon levels in patients with type 2 diabetes mellitus (T2DM). This compound is valuable for research applications focused on the regulation of glucose homeostasis and the therapeutic potential in metabolic disorders. -
DPP-4 Inhibitor
Cofrogliptin is a potent oral dipeptidyl peptidase-4 (DPP-4) inhibitor. It exhibits long-acting antidiabetic efficacy, making it a promising candidate for the management of type 2 diabetes mellitus (T2DM). Cofrogliptin's mechanism of action enhances incretin levels, which supports insulin secretion and regulates glucose metabolism. This compound is valuable for research applications focused on diabetes treatment and metabolic disorders. -
DPP-4 Inhibitor
Sitagliptin fenilalanil is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor that plays a crucial role in the regulation of glucose metabolism. By blocking the activity of DPP-4, it increases levels of incretin hormones, which enhance insulin secretion in response to meals and reduce glucagon levels. This compound is primarily utilized in diabetes research to explore therapeutic strategies for improving glycemic control and understanding the mechanisms of insulin regulation. -
DPP IV Inhibitor
Diprotin B is an inhibitor of dipeptidyl peptidase IV (DPP IV). By exhibiting competitive inhibition, Diprotin B mimics substrate behavior due to its tripeptide structure, particularly the presence of a proline residue at the penultimate position. This compound is utilized in research to study the modulation of glucose metabolism and to explore potential therapeutic applications in diabetes and related metabolic disorders. -
DPP-4 Inhibitor
Fotagliptin benzoate is a potent Dipeptidyl Peptidase IV (DPP-4) inhibitor with an IC50 value of 2.27 nM. It demonstrates a favorable safety profile in both rat and canine models. This compound is primarily utilized in research related to Type 2 diabetes mellitus, providing insights into glucose metabolism and potential therapeutic interventions. -
DPP1 Inhibitor
Propyl-GSK-2793660 hydrochloride is an irreversible and covalent inhibitor of Dipeptidyl Peptidase I (DPP1). This compound demonstrates significant inhibition of DPP1 activity, making it a valuable tool for investigating mechanisms related to bronchiectasis. Its application in research may facilitate the understanding of DPP1's role in various biological processes and potential therapeutic avenues. -
DPP-4 Inhibitor
Fotagliptin is a potent Dipeptidyl Peptidase IV (DPP-4) inhibitor with an IC50 of 2.27 nM. This compound is characterized by its favorable safety profile in rodent and canine models. Fotagliptin is primarily utilized in research related to Type 2 diabetes mellitus, contributing to investigations aimed at understanding glycemic control and insulin secretion mechanisms. -
DPP-4 Inhibitor
Sitagliptin fenilalanil hydrochloride is a potent inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme involved in glucose metabolism. By blocking DPP-4 activity, this compound enhances the levels of incretin hormones, which promotes insulin secretion and lowers glucagon levels, thereby improving glycemic control. It is primarily used in research applications related to diabetes mellitus and metabolic disorders. -
DPP-IV Inhibitor
PK44 phosphate is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV) with an IC50 value of 15.8 nM. It plays a critical role in regulating glucose metabolism and has potential applications in the treatment of type 2 diabetes. PK44 phosphate may also be used in pharmacological studies to explore the therapeutic effects of DPP-IV inhibition. -
DPP-4 Inhibitor
Teneligliptin-d8 is a deuterium-labeled analog of Teneligliptin, a competitive and durable inhibitor of dipeptidyl peptidase-4 (DPP-4). This compound is utilized in research to study the pharmacokinetics and metabolic pathways of Teneligliptin. Its potent inhibition of DPP-4 makes it significant for investigating therapeutic strategies for type 2 diabetes and related metabolic disorders. -
DPP II Substrate
Lys-Ala-pNA is a hydrolytic substrate specifically designed for dipeptidyl peptidase II (DPP II). Exhibiting a Michaelis constant (Km) of 0.42 mM, it serves as an effective tool for studying DPP II activity. This substrate is valuable in researching metabolic disorders and understanding DPP II's role in various physiological processes. -
DPP1 Inhibitor
AZD5248 is a selective inhibitor of dipeptidyl peptidase 1 (DPP1), a key enzyme involved in the regulation of peptide homeostasis. This compound demonstrates significant biological activity in the modulation of immune responses and is particularly relevant for research in chronic obstructive pulmonary disease (COPD) and other inflammatory lung disorders. Its ability to inhibit DPP1 makes it a valuable tool for investigating the therapeutic potential in respiratory diseases. -
DPP-4 Inhibitor
Evogliptin hydrochloride is a potent and selective inhibitor of Dipeptidyl Peptidase-4 (DPP-4), primarily utilized to enhance glycemic control in the management of type 2 diabetes. Its mechanism involves significant and sustained hypoglycemic effects while also reducing inflammatory and fibrotic signals in hepatocytes through the induction of autophagy. This compound is relevant for research exploring metabolic disorders, including type 2 diabetes, renal impairment, osteoporotic changes, and chronic liver inflammation. -
DPP4 Inhibitor
Dutogliptin tartrate is a potent and selective dipeptidyl peptidase-4 (DPP4) inhibitor. It demonstrates significant biological activity in the modulation of incretin hormones, thereby enhancing insulin secretion and lowering glucose levels. This compound is primarily utilized in research focused on the management and treatment of type 2 diabetes mellitus, contributing to the understanding of glucose metabolism and the role of DPP4 in diabetic pathophysiology. -
DPP-4 Inhibitor
Anagliptin hydrochloride is a potent and selective inhibitor of dipeptidyl peptidase 4 (DPP-4), exhibiting an IC50 of 3.8 nM. It demonstrates reduced selectivity for DPP-8 and DPP-9, with IC50 values of 68 nM and 60 nM, respectively. This compound is utilized in research focused on glycemic control and has applications in studying Type 2 diabetes and related metabolic disorders. -
DPP9 Inhibitor
DPP9-IN-2 is a selective, potent inhibitor of Dipeptidyl Peptidase 9 (DPP9), exhibiting an IC50 of 12.9 nM. It demonstrates a selectivity index of 59 over DPP8 and shows minimal inhibitory effects on related peptidases, including DPP2, DPP4, FAP, and PREP. DPP9-IN-2 has been shown to induce pyroptosis in cancer cells and exhibits weak synergistic anti-HIV-1 activity when combined with non-nucleoside reverse transcriptase inhibitors. This compound is suitable for research related to cancer and infectious diseases. -
DPP-IV Inhibitor
NVP-DPP728 dihydrochloride is a selective and potent inhibitor of dipeptidyl peptidase IV (DPP-IV), with a Ki value of 11 nM. This compound plays a critical role in the regulation of glucose metabolism and is utilized in research related to diabetes mellitus. NVP-DPP728 dihydrochloride offers valuable insights into the therapeutic potential of DPP-IV inhibition in glycemic control and metabolic diseases. -
DPP-4 Inhibitor
ZY15557 is a novel competitive DPP-4 inhibitor with a Ki of 5.53 nM, demonstrating significant potency in inhibiting plasma DPP-4 activity. This orally active compound is useful in the investigation of type 2 diabetes and its potential therapeutic strategies. Research applications include studying glucose metabolism and insulin secretion modulation associated with DPP-4 inhibition. -
DPP-IV Inhibitor
RBx-0597 is a selective inhibitor of Dipeptidyl Peptidase IV (DPP-IV), exhibiting IC50 values of 32 nM, 31 nM, and 39 nM for human, mouse, and rat plasma DPP-IV, respectively. This compound shows promise in the investigation of type 2 diabetes by modulating glucose metabolism and incretin levels, making it a valuable tool for diabetes research and related metabolic studies. -
DPP-IV Inhibitor
O-Benzoylhydroxylamine is a selective inhibitor of Dipeptidyl Peptidase IV (DPP-IV), a key enzyme involved in glucose metabolism. By inhibiting DPP-IV, this compound exhibits significant anti-diabetic effects, making it valuable for research into diabetes management and related metabolic disorders. Its mechanisms and targets are critical for understanding the pathways influenced by DPP-IV inhibition. -
DPP4 Inhibitor
ASP4000 hydrochloride is a potent, selective inhibitor of dipeptidyl peptidase IV (DPP4), exhibiting an IC50 value of 2.25 nM against human recombinant DPP4. This compound demonstrates significant antihyperglycemic effects, making it valuable in studies related to type 2 diabetes research. Its oral bioavailability and competitive inhibition profile allow for potential applications in understanding DPP4's role in glucose metabolism and diabetes management. -
DPP4 Inhibitor
ZINC000003015356 is a DPP4 inhibitor that selectively blocks the activity of the dipeptidyl peptidase-4 enzyme. This inhibition enhances the availability of incretin hormones, which are crucial for glucose metabolism. ZINC000003015356 is primarily used in research related to diabetes and metabolic disorders, contributing to studies focused on glycemic control and potential therapeutic strategies. -
DPP-IV Inhibitor
H-Pro-Pro-Gln-OH is an oligopeptide that acts as a potent inhibitor of dipeptidyl peptidase-IV (DPP-IV). This compound exhibits significant biological activity in modulating insulin secretion and glucose metabolism, making it a valuable tool for diabetes research. Its effective inhibition of DPP-IV may contribute to therapeutic strategies in managing type 2 diabetes and related metabolic disorders. -
DPP-8/9 Inhibitor
DPP-8/9 probe-1 is a selective inhibitor targeting Dipeptidyl Peptidase DPP8/9, designed for use in fluorescence microscopy. This fluorescent probe features a nitrobenzoxadiazole (NBD) tag, demonstrating high affinity for DPP8/9 with an IC50 of 15 nM, while showing minimal activity against related S9 family members (IC50 of 210 nM). DPP-8/9 probe-1 enables visualization of active DPP8/9 in vitro, making it a valuable tool for studying the biological functions and pathways associated with this enzyme in research settings. -
DPP1 Inhibitor
Florensocatib hydrate is a potent inhibitor of dipeptidyl peptidase I (DPP1) with an IC50 value of 1.6 nM. This compound exhibits favorable bioavailability and pharmacokinetic properties, making it suitable for studies investigating inflammatory diseases and related pathophysiological processes. Its ability to modulate DPP1 activity provides a valuable tool for understanding disease mechanisms and exploring potential therapeutic strategies. -
DPP-IV Inhibitor
AMG-222 is a dipeptidyl peptidase IV (DPP-IV) inhibitor that reversibly binds to the enzyme, thereby inhibiting its activity. This compound demonstrates a saturable and concentration-dependent binding to human plasma proteins, achieving a binding rate of 80.8% at 1 nM and decreasing to 29.4% at concentrations above 100 nM. AMG-222 is primarily utilized in diabetes research, aiding studies focused on glucose metabolism and insulin regulation. -
Anti DPP3 Antibody
Invobenitug is a humanized IgG1κ antibody that specifically targets dipeptidyl peptidase 3 (DPP3). This antibody is primarily utilized in research applications focused on understanding the role of DPP3 in various physiological and pathological processes. Its specificity and affinity make it an essential tool for studies related to cellular signaling, metabolism, and disease mechanisms involving DPP3. -
DPP4 Inhibitor
BMS-767778 is a selective DPP4 inhibitor, exhibiting high affinity with Ki values of 0.94 nM for DPP4, and 4.9 nM and 3.2 nM for DPP8 and DPP9, respectively, demonstrating over 3,000-fold selectivity against these related enzymes. This compound also inhibits CYP-3A4 with an IC50 of 5.2 μM. BMS-767778 has been shown to significantly lower blood glucose levels in high-fat diet-induced ob/ob mouse models, indicating its potential for diabetes mellitus research applications. -
DPP-4 Inhibitor
DPP-4-IN-1 is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4) with an IC50 of 49 nM. This compound, structurally analogous to Alogliptin, plays a crucial role in regulating glucose metabolism and enhancing insulin secretion. DPP-4-IN-1 is essential for diabetes research, facilitating investigations into therapeutic strategies for managing hyperglycemia. -
DPP-4 Inhibitor
Denagliptin tosylate is a tosyate salt of Denagliptin, functioning as a potent dipeptidyl peptidase IV (DPP-4) inhibitor. This small molecule effectively enhances incretin levels, contributing to improved glycemic control in type 2 diabetes models. Its applications in research include investigating mechanisms of insulin secretion and glucose metabolism, making it a valuable tool for diabetes-related studies. -
DPP-4 Inhibitor
DPP-4-IN-9 is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4) with an IC50 of 8.22 nM. This compound exhibits significant antihyperglycemic activity, making it a valuable tool for research in diabetes and metabolic disorders. DPP-4-IN-9 is suitable for studies aimed at understanding the role of DPP-4 in glucose metabolism and the development of therapeutic agents targeting this pathway. -
DPP1 Inhibitor
Florensocatib is a potent inhibitor of Dipeptidyl Peptidase I (DPP1), a key enzyme involved in the processing of pro-inflammatory cytokines. This compound exhibits significant biological activity, making it a valuable tool for research in bronchiectasis and related inflammatory diseases. Its selective inhibition of DPP1 provides insights into therapeutic strategies aimed at modulating immune responses. -
DPP-4 Inhibitor
DPP-4-IN-2 is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4) with an IC50 of 79 nM. This compound serves as a structural analog of Alogliptin and is primarily utilized in diabetes research. DPP-4-IN-2 facilitates the investigation of glucose metabolism and insulin signaling pathways, making it a valuable tool for understanding the pathophysiology of type 2 diabetes and developing potential therapeutic strategies. -
DPP1 Inhibitor
DPP-1-IN-1 is a potent inhibitor of Cathepsin C (Dipeptidyl peptidase I) with an IC50 of 5.31 nM. It effectively inhibits the activity of Cathepsin C, subsequently affecting Neutrophil elastase in neutrophils. This compound is valuable for research in the field of inflammatory diseases, providing insights into mechanisms of inflammation and potential therapeutic pathways. -
DPP-4 Inhibitor
TAK-100 is a selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitor, exhibiting an IC50 of 5.3 nM. This compound demonstrates minimal inhibitory effects on other dipeptidyl peptidases, highlighting its specificity. TAK-100 is primarily utilized in research focused on diabetes, facilitating the exploration of glucose metabolism and insulin regulation.
